stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Return on invested capital
Praxis Precision Medicines, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −40.6%, up 32.5 percentage points from fiscal 2025 (−73.1%). Over the past ten years it has ranged from −236.6% (fiscal 2024) to 0.00% (fiscal 2023); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −73.1% | 163.45 |
| FY2024 | −236.6% | (236.57) |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 27.2% |
| CORT Corcept Therapeutics Incorporated compare | 15.0% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 0.00% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | 0.00% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| ABVX Abivax SA Sponsored ADR compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| PRAX Praxis Precision Medicines, Inc. | −40.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)